Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Cancer Res. 2011 Feb 23;17(11):3794–3802. doi: 10.1158/1078-0432.CCR-10-2056

Table 5.

Pharmacokinetic parameters of SJG-136 following daily × 3 intravenous administration of 20, 25, 30 or 35 µg/m2/day SJG-136 (Schedule B).

SJG-136 Dose Level (µg/m2/day)
20 (n=3) 25 (n=3) 30 (n=5) 35 (n=2)
Cmax
(ng/mL)
C1D1 6.41 (1.10) 5.97 (1.76) 9.51 (2.09) 13.63
C1D3 6.12 (2.47) 5.52 (2.24) 7.84 (3.57) 9.85
C2D1 7.68 (3.70) 6.45 (0.80) 9.61 (2.59) 14.17
C2D3 6.92 (3.68) 4.60 (0.46) 6.91 (1.48) 9.23

AUCinf
(ng•min/mL)
C1D1 254 (116) 303 (73) 439 (140) 575
C1D3 273 (169) 306 (155) 372 (152) 450
C2D1 426 (247) 335 (48) 455 (213) 641
C2D3 376 (255) 244 (39) 319 (120) 402

Half-life
(min)
C1D1 74.3 (17.4) 99.5 (24.0) 85.5 (17.4) 65.3
C1D3 48.5 (20.4) 91.9 (10.4) 96.9 (16.3) 77.2
C2D1 77.3 (24.6) 81.7 (17.8) 82.3 (11.5) 69.2
C2D3 87.8 (28.9) 94.3 (7.1) 76.9 (10.5) 74.5

CL
(mL/min/m2)
C1D1 88.7 (32.9) 86.1 (23.5) 73.2 (19.8) 61.9
C1D3 91.7 (46.0) 95.2 (40.7) 92.3 (38.3) 78.1
C2D1 57.0 (26.9) 75.7 (11.6) 75.5 (27.2) 55.7
C2D3 69.1 (36.1) 103.9 (15.1) 104.5 (35.3) 89.3

Vss
(mL/m2)
C1D1 4730 (553) 7630 (2590) 4860 (911) 3120
C1D3 3920 (1930) 8070 (3700) 7370 (2720) 5020
C2D1 4540 (3180) 6050 (1300) 5060 (1510) 3170
C2D3 5600 (3990) 8760 (1180) 6810 (2240) 5570